Deauville five-point scale
Citation, DOI, disclosures and article data
At the time the article was created René Pfleger had no recorded disclosures.View René Pfleger's current disclosures
The Deauville five-point scale (Deauville 5PS) is an internationally-recommended scale for routine clinical reporting and clinical trials using FDG PET-CT in the initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL).
FDG-PET-CT for staging and treatment response in both clinical routine and clinical trials using the Deauville five-point scale is recommended in 2:
Hodgkin lymphoma (HL), any type
marginal zone NHL with an aggressive transformation
FDG-avid nodal lymphomas, essentially all histologic types except:
whereas there have been proposed separate criteria for 2:
primary extranodal and
It is a simple tool based on visual interpretation of FDG uptake. It takes advantage of two reference points of the individual patient, which have demonstrated relatively constant uptake on serial imaging. The two reference organs are the mediastinum (a.k.a. blood pool) and the liver.
The scale ranges from 1 to 5, where 1 is best and 5 is the worst. Each FDG-avid (or previously FDG-avid) lesion is rated independently:
no uptake or no residual uptake (when used interim)
slight uptake, but equal to or below blood pool (mediastinum)
uptake above mediastinal, but below or equal to uptake in the liver
uptake slightly to moderately higher than liver
markedly increased uptake or any new lesion (on response evaluation)
Some authors also use:
X for any lesion not overtly attributable to lymphoma 6
Assessment of treatment response
complete response (CR): scores 1, 2 or 3 together with the absence of FDG-avid bone marrow lesion(s) are interpreted as complete metabolic response (CR), irrespective of a persistent mass on CT
partial response (PR): a Deauville score of 4 or 5, provided:
uptake is decreased compared with baseline and
absence of structural progression development on CT
stable disease (SD), also called no metabolic response: a Deauville score of 4 or 5 without significant change in FDG uptake from baseline.
progressive disease (PD): a Deauville score of 4 to 5 with increasing intensity compared to baseline or any interim scan and/or any new FDG-avid focus consistent with malignant lymphoma 7
It is often stated that DLBCL patients who demonstrate a complete metabolic response (Deauville 1) but have a residual mass of greater than 2 cm are at an increased risk of recurrence.
History and etymology
The scale was proposed in an international workshop attended by hematologists and nuclear medicine specialists in Deauville, France in 2009 4,5.
- 1. Barrington S, Mikhaeel N, Kostakoglu L et al. Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32(27):3048-58. doi:10.1200/JCO.2013.53.5229 - Pubmed
- 2. Cheson B, Fisher R, Barrington S et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 2014;32(27):3059-68. doi:10.1200/JCO.2013.54.8800 - Pubmed
- 3. Gallamini A, Barrington S, Biggi A et al. The Predictive Role of Interim Positron Emission Tomography for Hodgkin Lymphoma Treatment Outcome is Confirmed Using the Interpretation Criteria of the Deauville Five-Point Scale. Haematologica. 2014;99(6):1107-13. doi:10.3324/haematol.2013.103218 - Pubmed
- 4. Biggi A, Gallamini A, Chauvie S et al. International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers. J Nucl Med. 2013;54(5):683-90. doi:10.2967/jnumed.112.110890 - Pubmed
- 5. Barrington S, Qian W, Somer E et al. Concordance Between Four European Centres of PET Reporting Criteria Designed for Use in Multicentre Trials in Hodgkin Lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-33. doi:10.1007/s00259-010-1490-5 - Pubmed
- 6. Moskowitz C. Interim PET-CT in the Management of Diffuse Large B-Cell Lymphoma. Hematology Am Soc Hematol Educ Program. 2012;2012:397-401. doi:10.1182/asheducation-2012.1.397 - Pubmed
- 7. Dabaja B, Phan J, Mawlawi O et al. Clinical Implications of Positron Emission Tomography-Negative Residual Computed Tomography Masses After Chemotherapy for Diffuse Large B-Cell Lymphoma. Leuk Lymphoma. 2013;54(12):2631-8. doi:10.3109/10428194.2013.784967 - Pubmed